-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[ Star Enterprise of Chemical Machinery and Equipment Network ] Recently, Beijing Labtech Instrument Co.
, Ltd.
(stock abbreviation: Labtech, stock code: 688056) released the 2021 annual performance bulletin announcement
.
Chemical Machinery Equipment Net Star Enterprise Chemical Machinery Equipment, Ltd.
(stock abbreviation: Labtech, stock code: 688056) released the 2021 annual performance bulletin announcement
.
In 2021, Labtech will realize an operating income of 3.
694 million yuan, a year-on-year increase of 5.
97%; an operating profit of 767.
8 million yuan, a year-on-year increase of 10.
91%; a total profit of 817.
7 million yuan, a year-on-year increase of 7.
02%; The net profit attributable to the owners of the parent company was RMB 701.
9 million, a year-on-year increase of 7.
65%; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was RMB 637.
7 million, a year-on-year increase of 9.
33%
.
694 million yuan, a year-on-year increase of 5.
97%; an operating profit of 767.
8 million yuan, a year-on-year increase of 10.
91%; a total profit of 817.
7 million yuan, a year-on-year increase of 7.
02%; The net profit attributable to the owners of the parent company was RMB 701.
9 million, a year-on-year increase of 7.
65%; the net profit attributable to the owners of the parent company after deducting non-recurring gains and losses was RMB 637.
7 million, a year-on-year increase of 9.
33%
.
In 2021, due to the frequent occurrence of the epidemic, Labtech's business has been affected to a certain extent.
Although the company's operating income and operating profit have increased, the magnitude is not high
.
Labtech's new product inductively coupled plasma mass spectrometer (ICP-MS) in 2021 has been widely concerned by the market and investors since the product was released.
, medical and traditional fields have obtained corresponding orders or cooperation agreements, but the launch time is still short, and there is no significant contribution to the performance in 2021
.
Although the company's operating income and operating profit have increased, the magnitude is not high
.
Labtech's new product inductively coupled plasma mass spectrometer (ICP-MS) in 2021 has been widely concerned by the market and investors since the product was released.
, medical and traditional fields have obtained corresponding orders or cooperation agreements, but the launch time is still short, and there is no significant contribution to the performance in 2021
.
Labtech implemented an equity incentive plan in 2021, and the share-based payment expense included in the reporting period was RMB 3.
346 million.
If the after-tax amount of share-based payment is deducted, the amount attributable to the owner of the parent company after deducting non-recurring gains and losses.
Net profit was 66.
5699 million yuan, an increase of 14.
12% compared with the same period last year
.
346 million.
If the after-tax amount of share-based payment is deducted, the amount attributable to the owner of the parent company after deducting non-recurring gains and losses.
Net profit was 66.
5699 million yuan, an increase of 14.
12% compared with the same period last year
.
In the first three quarters of 2021, the operating income of Labtech was RMB 2,687,907,000, a year-on-year increase of 19.
39%; the net profit attributable to shareholders of listed companies was RMB 533,222,000, a year-on-year increase of 47.
02%; Net profit from recurring gains and losses was RMB 50,012,000, a year-on-year increase of 33.
05%
.
The quarterly results are as follows:
39%; the net profit attributable to shareholders of listed companies was RMB 533,222,000, a year-on-year increase of 47.
02%; Net profit from recurring gains and losses was RMB 50,012,000, a year-on-year increase of 33.
05%
.
The quarterly results are as follows:
About Labtech
Beijing Labtech Instrument Co.
, Ltd.
focuses on the research and development of scientific instruments and equipment, and is determined to provide practical and reliable laboratory equipment and overall solutions for many basic science and industrial applications such as environmental testing, food safety, medical hygiene, disease control, and materials research.
scheme
.
Products and services cover laboratory analytical instruments , sample pretreatment instruments, laboratory equipment, medical equipment, laboratory consumables and laboratory engineering construction
.
The company owns industry brands such as LabTech, CDS, and Empore.
It has R&D and production bases in China and the United States, as well as product marketing and service centers in Beijing, China, Hong Kong, and Boston, the United States
.
Analytical Instruments , Ltd.
focuses on the research and development of scientific instruments and equipment, and is determined to provide practical and reliable laboratory equipment and overall solutions for many basic science and industrial applications such as environmental testing, food safety, medical hygiene, disease control, and materials research.
scheme
.
Products and services cover laboratory analytical instruments , sample pretreatment instruments, laboratory equipment, medical equipment, laboratory consumables and laboratory engineering construction
.
The company owns industry brands such as LabTech, CDS, and Empore.
It has R&D and production bases in China and the United States, as well as product marketing and service centers in Beijing, China, Hong Kong, and Boston, the United States
.
Original title: Libtech's 2021 profit exceeds 300 million yuan and its annual performance shows a slight increase
